The underlying causes of eye movement disorders and ataxia.

Neurodegener Dis ManagOct 31, 2025 (epub)
Case ReportNeurology

Nannan Qian, Chengcheng Lu, Yufei Qian et al.

✦ AI-curated · Sources linked

Case in brief

A 54-year-old Chinese woman presented with progressive gait instability and slowed speech, with mild bradykinesia and frequent backward falls. Examination showed supranuclear gaze palsy, hyporeflexia, and cerebellar dysfunction (SARA 26/40). MSA, SCA, and PD were considered; genetic testing excluded SCA, and advanced imaging ruled out other disorders. She met criteria for probable PSP-C. [18F]PM-PBB3 tau PET showed abnormal tau accumulation in the striatum, thalamus, midbrain, and pons, consistent with PSP-C neuropathology.

What made this case unusual

The presentation combined cerebellar ataxia with features that overlap other movement disorders, while tau PET showed a distribution consistent with PSP-C neuropathology.

Diagnostic / clinical pearl

In a patient with ataxia and overlapping parkinsonian or gaze abnormalities, PSP-C should be considered; tau PET may help distinguish it from other disorders.

Why it matters

The report adds tau PET imaging evidence for PSP-C in an Asian patient, supporting further consideration of noninvasive tau-targeted imaging in its evaluation.

Source

Published in Neurodegener Dis Manag. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.